A detailed history of Tower Research Capital LLC (Trc) transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 391 shares of JANX stock, worth $19,671. This represents 0.0% of its overall portfolio holdings.

Number of Shares
391
Previous 2,580 84.84%
Holding current value
$19,671
Previous $108,000 84.26%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$35.29 - $50.26 $77,249 - $110,019
-2,189 Reduced 84.84%
391 $17,000
Q2 2024

Aug 13, 2024

BUY
$35.12 - $64.78 $46,393 - $85,574
1,321 Added 104.92%
2,580 $108,000
Q1 2024

May 15, 2024

SELL
$7.93 - $49.75 $4,036 - $25,322
-509 Reduced 28.79%
1,259 $47,000
Q4 2023

Feb 13, 2024

BUY
$5.85 - $11.7 $2,691 - $5,382
460 Added 35.17%
1,768 $18,000
Q3 2023

Nov 14, 2023

SELL
$9.56 - $14.0 $2,762 - $4,046
-289 Reduced 18.1%
1,308 $13,000
Q2 2023

Aug 14, 2023

SELL
$11.08 - $15.92 $19,356 - $27,812
-1,747 Reduced 52.24%
1,597 $18,000
Q1 2023

May 09, 2023

BUY
$11.25 - $22.21 $22,533 - $44,486
2,003 Added 149.37%
3,344 $40,000
Q4 2022

Feb 10, 2023

BUY
$11.1 - $18.26 $2,064 - $3,396
186 Added 16.1%
1,341 $18,000
Q3 2022

Nov 10, 2022

SELL
$10.82 - $16.84 $8,753 - $13,623
-809 Reduced 41.19%
1,155 $16,000
Q2 2022

Aug 15, 2022

BUY
$9.52 - $15.65 $6,873 - $11,299
722 Added 58.13%
1,964 $24,000
Q1 2022

May 12, 2022

SELL
$13.24 - $20.24 $1,880 - $2,874
-142 Reduced 10.26%
1,242 $18,000
Q4 2021

Feb 14, 2022

BUY
$15.44 - $27.32 $13,309 - $23,549
862 Added 165.13%
1,384 $27,000
Q3 2021

Nov 15, 2021

BUY
$20.7 - $34.69 $10,805 - $18,108
522 New
522 $11,000

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.1B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.